SOURCE: Xtalks

Xtalks Webinars

June 13, 2016 07:00 ET

Hemocompatibility: Preclinical Biological Evaluation of Medical Devices for Interaction With Blood, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - June 13, 2016) - During a live session on Wednesday, June 29, 2016, industry expert Dr. Frank Grall, Department Head of In-Vitro Services at Toxikon Corporation, will present various aspects of hemocompatibility testing, such as:

  • Selection of tests,
  • Identification of what devices need to be tested, and
  • What part of the device needs testing.

Grall will also cover some technical details about how the various tests function:

  • Chemically and mechanically induced hemolysis,
  • Pro-coagulant effect,
  • Effect on platelets and leukocytes, and
  • Activation of the complement.

Before being used in humans, medical devices need, in general, to have some testing performed in order to assess their safety profile. This biocompatibility assessment includes various endpoints, among which a certain number are focused on the potential effect on blood -- also known as hemocompatibility.

Even within the cardiovascular field, the type of blood contact may vary from non-contact, indirect, external communicating with direct contact, or for implanted devices. Official guideline documents such as ISO 10993-4, provide direction for deciding whether testing for interaction with blood is necessary. Complex phenomenon such as the hemostasis can be best monitored in-vivo, with the device used the way it is intended. When testing is performed in-vitro, an appropriate model or system should be used that simulates closely enough the clinical situation, so that these pre-clinical results possess enough predictive value. The appropriate choice of controls, as well a clear identification of the test article, (or the part(s) thereof), is also critical as part of a proper strategy to allow smooth regulatory review such as 510K or CE mark.

Both in-vitro and in-vivo models can be used for this purpose, each being set up with the goal of mimicking clinical application and allowing assessment of the proper end-point.

Whether the blood contact is direct or indirect, each device needs to be considered for their hemocompatibility, such as hemolysis, thrombosis, platelet activation, hematology and complement activation.

Devices that are involved in the circulation of blood, like cardiopulmonary bypass systems or apheresis equipment, may compromise hemocompatibility, damaging the red blood cells by mechanical means. Other devices may manifest some hemolytic potential via their chemical composition, either as extractable or leachable, or by direct contact of the red blood cells with the device.

As foreign materials, medical devices can activate the coagulation cascade. The resulting thrombus, either on the surface of the devices or dislodged, may be the source of serious complications. Some membranes used in hemodialysis have been linked to complement activation, leading to pulmonary distress and coagulation disorders.

A proper selection of the most applicable tests is therefore essential to detect and predict any deleterious interaction between the devices and the blood.

For more information or to register for this complimentary event, visit: Hemocompatibility: Preclinical Biological Evaluation of Medical Devices for Interaction with Blood

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Image Available:

Contact Information